Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift

At the 12th Annual Cantor Fitzgerald Global Healthcare Conference, Xencor (XNCR) signaled a shift from its platform licensing model to a late-stage drug development strategy centered on its XmAb medicines. The company highlighted scientific progress and upcoming data events, while also noting that some programs require stronger evidence of competitive advantage before advancing further.

XmAb819, a wholly-owned ENPP3-targeted T-cell engager in renal cell carcinoma, is the primary program driving this shift, with a potential registration-enabling study planned for 2025. This program demonstrated a 25% objective response rate in early data, with additional durability data from an ESMO update expected in about a month.

Xencor also announced a strategic decision to stop XmAb541 monotherapy development and instead pursue combination approaches. The company is advancing two TL1A programs in inflammatory bowel disease and an autoimmune bispecific, while continuing partner programs with Astellas and Johnson & Johnson in pivotal testing. Xencor aims to develop best-in-class or clearly differentiated products, not incremental ones.

The company's broader solid tumor and immune programs are designed to achieve unique profiles, not just incremental improvements.